Moolec Science (NASDAQ:MLEC – Get Free Report) is one of 673 public companies in the “Holding & other investment offices” industry, but how does it compare to its peers? We will compare Moolec Science to related companies based on the strength of its analyst recommendations, profitability, institutional ownership, dividends, earnings, risk and valuation.
Institutional and Insider Ownership
0.1% of Moolec Science shares are owned by institutional investors. Comparatively, 54.2% of shares of all “Holding & other investment offices” companies are owned by institutional investors. 19.9% of Moolec Science shares are owned by company insiders. Comparatively, 26.8% of shares of all “Holding & other investment offices” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Earnings & Valuation
This table compares Moolec Science and its peers top-line revenue, earnings per share and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
Moolec Science | $5.63 million | -$7.31 million | -4.25 |
Moolec Science Competitors | $1.01 billion | $81.17 million | 62.23 |
Volatility and Risk
Moolec Science has a beta of -0.54, suggesting that its stock price is 154% less volatile than the S&P 500. Comparatively, Moolec Science’s peers have a beta of 0.03, suggesting that their average stock price is 97% less volatile than the S&P 500.
Profitability
This table compares Moolec Science and its peers’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Moolec Science | -129.97% | -97.95% | -27.91% |
Moolec Science Competitors | -17.66% | -43.09% | -0.30% |
Analyst Ratings
This is a summary of recent recommendations and price targets for Moolec Science and its peers, as reported by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Moolec Science | 0 | 0 | 1 | 0 | 3.00 |
Moolec Science Competitors | 128 | 730 | 961 | 19 | 2.47 |
Moolec Science currently has a consensus target price of $6.00, indicating a potential upside of 605.88%. As a group, “Holding & other investment offices” companies have a potential upside of 51.71%. Given Moolec Science’s stronger consensus rating and higher probable upside, analysts plainly believe Moolec Science is more favorable than its peers.
Summary
Moolec Science peers beat Moolec Science on 10 of the 13 factors compared.
About Moolec Science
Moolec Science SA, a science-based food ingredient company, focuses on developing real animal proteins in plants using molecular farming. It offers Chymosin SPC, a dairy ingredient; GLA SONOVA, a nutritional oil; POORK+, a plant-based, animal meat free ingredient with porcine proteins in soybeans; and BEEF+, a meat replacement product. It operates in the United States, Europe, and South America. The company was founded in 2020 and is based in Luxembourg.
Receive News & Ratings for Moolec Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moolec Science and related companies with MarketBeat.com's FREE daily email newsletter.